Vaxart Inc.

Clinical‑stage biotech Vaxart develops oral recombinant protein vaccines on a proprietary platform, with Phase‑2 candidates for norovirus, COVID‑19 & influenza; preclinical HPV vaccine and a partnership to commercialize broad‑spectrum antiviral Vapendavir.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 105
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
VXRT	Vaxart Inc. Cap: 0.2B	EQUITY	NMS	USD	US92243A2006	Active	📈